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Available online 4 April 2016AbstractBackground & aims: Carcinoembryonic antigen (CEA) is a tumour marker whose role is now being evaluated as a biomarker for early diagnosis
of acute coronary syndromes. Its levels may rise even prior to rise of established biomarkers of myocardial necrosis.
Methods: Serum CEA concentrations were measured by double sandwich ELISA method in four groups of subjects with STEMI, NSTEMI/UA
(24 patients of NSTEMI and 18 patients of unstable angina), stable angina and healthy controls with 42 males between 40 to 60 years of age in
each group. Also qualitative Troponin T assay and CPK-MB concentrations measurement was done in groups with STEMI and NSTEMI/UA and
correlations between CEA concentrations and Troponin T and CPK-MB were made.
Results: Mean serum CEA concentrations were 5.19 ± 0.39, 3.84 ± 0.34, 3.91 ± 1.40, 1.84 ± 0.35 and 2.12 ± 0.40 ng/ml respectively in groups
with STEMI, NSTEMI/UA, UA alone, stable CAD and healthy controls respectively. STEMI, NSTEMI/UA and UA patients had significantly
higher concentrations than stable CAD and healthy controls (p < 0.001). CEA concentrations were comparable in stable CAD and healthy
controls (p ¼ 1.00). Mean serum CPK- MB concentration in group with STEMI was significantly higher than in NSTEMI/UA group (p < 0.001).
Highly significant positive correlation was obtained between mean CEA and CPK-MB concentrations in STEMI (R ¼ 0.866, p < 0.001) and
NSTEMI (R ¼ 0.950, p < 0.001), STEMI and NSTEMI combined together (R ¼ 0.781, p < 0.001) NSTEMI and UA together (R ¼ 0.648,
p < 0.001), but it was weak and statistically insignificant in UA patients (R ¼ 0.319, p ¼ 0.197). Mean serum concentration 4.69 ± 3.26 ng/ml of
CEA in patients with ACS was significantly higher in troponin T positive patients as compared to 3.91 ± 1.40 ng/ml in Troponin T negative
patients (p < 0.001).
Conclusions: CEA is a sensitive biomarker for early diagnosis of ACS. Its levels correlate with severity of ACS. It may play a crucial role in
diagnosis of ACS in patients who present with atypical manifestations or when traditional biomarkers such as CPK-MB and Troponins are not
raised.
Copyright © 2016, Taiwan Society of Emergency Medicine. Published by Elsevier Taiwan LLC. This is an open access article under the
CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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To predict the future has been the dream of human kinds for
thousands of years. Although, clinical manifestations and
pathognomonic ECG or echocardiographic findings have* Corresponding author. B-38/S2, Block-B, Dilshad Garden, Delhi 110095,
India. Tel.: þ91 011 9868399608; fax: þ91 011 22581289.
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http://dx.doi.org/10.1016/j.jacme.2016.03.002
2211-5587/Copyright© 2016, Taiwan Society of Emergency Medicine. Published b
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).taken a big step forward in the treatment of ACS, there is still
a no man's land in diagnosis when plasmin is struggling to
solve clots secondary to plaque rupture. Any cost-effective
method that can stratify the patients at this stage should be
very welcome.
Rupture of unstable atherosclerotic plaque is a major
mechanism of development of acute coronary syndrome
(ACS) from stable CAD. Currently, creatinine phosphokinase-
MB (CPK-MB) and cardiac troponins T and I are used toy Elsevier Taiwan LLC. This is an open access article under the CC BY-NC-ND
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(BNP), myeloperoxidase, pregnancy associated plasma
protein-A (PAPP-A) and metalloproteinase-9 are other re-
ported useful markers for diagnosis of ACS. However, the
availability of a sensitive and specific early bio marker of
plaque instability, whose levels become elevated before or
even in the absence of myocardial necrosis, should improve
diagnostic and therapeutic decision making.
Carcinoembryonic antigen (CEA) is a tumour marker
associated with various malignancies e.g. carcinoma colon,
lung, breast, thyroid, stomach etc. Some non neoplastic con-
ditions such as smoking, obesity, acute coronary syndromes,
inflammatory bowel disease, liver and kidney disease also
have been found to be associated with higher CEA concen-
trations.1e3 Carcinoembryonic antigen (CEA) might be one
such potential molecule which is being evaluated as a bio
marker for early diagnosis of acute coronary syndromes
(ACS). The hypothesis behind current study was that the
transformation from stable to unstable plaque might be re-
flected by rise in concentrations of CEA.
Recently CEA has been reported to be associated with
abdominal visceral fat in Korean non-smoker females.
Visceral fat is a powerful risk factor for atherosclerosis.4
Only scanty data is available in literature highlighting role
of CEA in CAD. A study, conducted on Japanese men, re-
ported significantly higher concentrations of CEA in patients
with carotid atherosclerosis as compared to healthy controls.5
However, another study reported higher concentrations of
CEA in patients with ACS but not in those with stable CAD.6
However, in this study patients with NSTEMI/UA were not
separately analysed. Moreover, correlation with CPK-MB and
Troponin T was not assessed. In view of above controversies
we planned this study.
2. Material and method
This analytical cross sectional study was carried out at a
tertiary hospital in north India between years 2011 to 2013 and
comprised of four groups with 42 male subjects, between 40-
60 years of age, in each group. These four groups namely- A,
B, C and D comprised of patients with STEMI, NSTEMI/UA,
stable angina and age and sex matched healthy controls. Out of
total 42 patients include in NSTEMI/UA group 24 patients had
NSTEMI while remaining 18 were diagnosed to have unstable
angina (UA). Patients with STEMI and NSTEMI were diag-
nosed on the basis of 2007 American heart association uni-
versal definition of acute myocardial infarction.7 Patients
included in stable angina group were those who were already
diagnosed chronic stable angina after appropriate clinical and
laboratory investigations and were already in follow up in
coronary clinic or newly diagnosed patients of stable angina
based on clinical history and stress tests such as treadmill test
(TMT), thallium scan, stress echocardiography or coronary
angiography. Control group included healthy attendants of
patients.
After obtaining written consent, a detailed history and
thorough physical examination were performed on allsubjects. Various anthropometric parameters like height,
weight and waist circumference were recorded. Patients with
any acute or chronic inflammatory conditions, past or present
malignancy, acute or chronic liver disease, chronic kidney
disease (Serum creatinine >1.5 mg/dl), multiorgan dysfunc-
tion syndromes, inflammatory bowel disease, smokers with
history of smoking for more than 50 pack years (1 bidi
considered equivalent to 1 cigarette) or those with positive test
for stool for occult blood were excluded from the study.
Routine laboratory investigations including complete blood
counts, blood sugar (fasting and postprandial), kidney function
tests such as serum blood urea, creatinine, liver function test
such as serum proteins, bilirubin, alkaline phosphatase, ALT
(alanine aminotransferase) and AST (aspartate aminotrans-
ferase), serum lipid parameters and 12 lead ECG were per-
formed on all subjects. Those with any evidence of liver or
kidney disease on investigations were excluded from study.
For routine haematological investigations, after overnight
fasting blood samples were collected in EDTA vial for blood
counts and plain vial for serum related investigations. Stool
sample for occult blood was also collected in the morning.
Special Investigations included Serum CEA concentrations
estimation (for all groups), for which 2 ml blood was taken in
plain vial as early as possible after presentation but not beyond
24 hours after onset of chest pain in groups A and B. In groups
C and D sample was at the time of recruitment. Vials were
transported to department of Biochemistry and stored in deep
freezer at 80C for further processing. Commercially avail-
able kits using double sandwich ELISA (Weldon Biotech,
India) for quantitative assessment of CEA levels were used for
estimation of its concentrations.
Qualitative cTn T test was done in groups A and B using
commercially available kit. Serum CPK-MB concentrations
were measured in groups A and B by immunoenzymatic
method8 using commercially available kit. Blood samples for
both Troponin T and serum CPK-MB levels were taken as
soon as possible after admission, but not beyond 24 hours of
onset of chest pain.
3. Statistical analysis
Software SPSS 17.0 was used to analyse the data. One way
Analysis of variance (ANOVA) was used to compare means
across the groups. Post-hoc Tukey's test was used for multiple
comparisons. Spearman's rank order correlation was used for
correlation between CEA and CPK-MB concentrations
(quantitative data) in groups A and B separately. Unpaired t-
test was used to compare mean CEA concentrations in
Troponin T positive patients and Troponin T negative patients
separately in groups A and B. A p-value <0.05 was considered
statistically significant and <0.001 as highly significant.
4. Results
There was a trend towards higher BMI, waist circumfer-
ence, waist hip ratio, blood sugar with increasing severity of
CAD i.e. highest values were found in STEMI followed by
Table 1
Baseline characteristics of the study groups.
Parameters
Mean ± SD
(Range or %)
Group A
(STEMI)
(n ¼ 42)
Group B
(NSTEMI/UA)
(n ¼ 42)
Group C
(Stable angina)
(n ¼ 42)
Group D
(Controls)
(n ¼ 42)
p-value
A vs B
A vs C
A vs D
p-value
B vs C
B vs D
C vs D
Age (years) 51.33 ± 6.03 (41e60) 51.02 ± 5.93 (40e59) 52.38 ± 6.48 (41e60) 49.50 ± 6.35 (41e59) 0.996
0.866
0.53
0.748
0.674
0.149
Body mass index (kg/m2) 28.41 ± 2.71 (21.64e33.30) 26.65 ± 3.18 (18.17e32.52) 24.86 ± 2.14 (18.38e0.13) 22.20 ± 2.26 (17.02e26.44) 0.013
<0.001
<0.001
0.011
<0.001
<0.001
Waist circumference (cm) 93.64 ± 8.96 (76e110) 92.47 ± 7.62 (78e108) 88.16 ± 6.88 (74e108) 84.23 ± 6.48 (74e94) 0.894
0.006
<0.001
0.048
<0.001
0.084
Hb (g%) 13.58 ± 1.31 (8.5e15.8) 13.90 ± 1.46 (9.8e16.8) 13.45 ± 1.321 (8.4e15.8) 12 ± 1.82 (7.8e15.1) 0.767
0.978
0.177
0.519
0.016
0.359
TLC (/mm3) 10700 ± 2970 (5800e17800) 9092.85 ± 2958.93 (5400e19800) 7643.33 ± 1126.86 (5400e9700) 7938.09 ± 1701.64 (4500e14200) 0.010
<0.001
<0.001
0.025
0.109
0.938
Fasting blood sugar (mg%) 109.28 ± 32.28 (74e210) 107.47 ± 27.00 (72e189) 96.57 ± 17.82 (78e165) 97.11 ± 24.46 (74e213) 0.989
0.115
0.142
0.220
0.263
1.000
Post prandial sugar (mg %) 151.11 ± 46.55 (97e298) 147.5 ± 36.98 (98e276) 140.97 ± 33.66 (102e286) 134.23 ± 30.10 (101e268) 0.971
0.601
0.168
0.855
0.368
0.842
Smokers 32 (76.2%) 32 (72.6%) 32 (76.2%) 32 (76.2%) 1.00
1.00
1.00
1.00
1.00
1.00
Bold indicate p-values significant at <0.05 and highly significant at <0.001.
All values have been described as mean ± SD (range).
Abbreviations: Hb- Hemoglobin,TLC- Total leucocytes count, STEMI- ST segment elevation myocardial infarction, NSTEMI/UA- Non ST segment elevation myocardial infarction/Unstable angina.
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Figure 1. Mean serum CEA of various groups after adjusting for confounding
factors.
-50
0
50
100
150
200
250
300
Group A (STEMI) Group B (NSTEMI/UA)
C
PK
-M
B
 (I
U
/d
l)
130.95 ± 108.32 
62.19 ± 67.33 
p<0.001
Figure 2. Mean serum CPK- MB of STEMI and NSTEMI/UA groups.
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(Table 1). After adjusting for confounding variables like age,
smoking status, BMI, blood sugar, total leucocytes count,
waist circumference, blood pressure, total and HDL-
cholesterol patients with STEMI had significantly higher
values of CEA as compared to patients with NSTEMI
(p < 0.05). Both STEMI and NSTEMI/UA group had signif-
icantly higher values of CEA as compared to stable angina
group (p < 0.001 and 0.001 respectively) (Figure 1). Patients
of UA had significantly higher concentration of CEA as
compared to stable CAD patients (p < 0.001, Table 2). There
was no statistically significant difference between stable
angina and controls group regarding serum CEA concentra-
tions (p ¼ 1.00) (Figure 1). Concentrations of CPK-MB were
significantly higher in patients with STEMI as compared to
NSTEMI/UA group (p < 0.001) (Figure 2).
The Intergroup correlation of the serum levels of CEAwith
the serum levels of CPK-MB was assessed in patients of
STEMI and NSTEMI/UA groups. The serum levels of CEA
had significant positive correlation with the serum levels of
CPK-MB in STEMI (R ¼ 0.866, p < 0.001) (Figure 3),
NSTEMI/UA (R ¼ 0.648, p < 0.001) (Figure 4) and STEMI
plus NSTEMI (R ¼ 0.781, p < 0.001) (Figure 5). However,
when UA patients and NSTEMI patients were analysed
separately, a strong correlation with NSTEMI was found
(R ¼ 0.950, p < 0.001) (Figure 6) but correlation with unstable
angina was insignificant (R ¼ 0.319, p ¼ 0.197) (Figure 7).
Also when patients of STEMI and NSTEMI/UAwere analysed
together, strong correlation was obtained between concentra-
tions of CEA and CPK-MB, which was highly significant
statistically (R ¼ 0.809, p < 0.001) (Figure 8). Mean serumTable 2
Comparison of CEA concentration in patients with unstable angina and stable
CAD.
Unstable angina
(n ¼ 18)
Stable CAD
(n ¼ 42)
P value
Mean CEA (ng/ml)
Range
3.91 ± 1.40 (1.10e6.80) 1.84 ± 0.35 (1.15e2.54) <0.001
p-value significant at <0.05 and highly significant at <0.001.concentration (4.69 ± 3.26 ng/ml) of CEA in Troponin T
positive (STEMI and NSTEMI) patients was significantly
higher when compared to (3.91 ± 1.40 ng/ml) in Troponin T
negative (UA) patients (p < 0.001) (Table 3). Also the serum
CEA levels were found to be significantly higher in Troponin
T negative ACS (UA) patients as compared to patients with
stable CAD and healthy controls (p < 0.001) (Tables 2 and 4).
5. Discussion
Even after adjusting for confounding variables patient with
ACS had significantly higher mean serum concentration of
CEA than stable CAD and healthy controls (p < 0.001).
Moreover, significant difference (p < 0.05) between STEMI
and NSTEMI/UA groups regarding CEA concentration high-
lights that this molecule can prove a useful marker for diag-
nosis of ACS and its concentrations correlate with severity of
CAD. This observation is further strengthened by finding
significant strong positive correlation with concentrations of
CPK-MB and Troponin T positivity which are well-
established markers to gauge severity of ACS. The results of
our study are in accordance with the pioneering work done by
Vassalle C et al.6 They also observed significantly higher
levels of CEA in patients of ACS as compared to stable angina
patients and healthy controls. Moreover, we also found
significantly higher concentration of CEA in patients with UA
as compared to patients with stable CAD, further highlighting
association of CEA with vulnerable plaque.
CEA is a cell surface adhesion molecule of immunoglob-
ulin superfamily. Somatic mutation theory has considered
similar pathogenic mechanisms for process of atherosclerosis
and tumourigenesis.9 Number of biochemical properties of
CEA such as expression of intercellular adhesion molecule-1
(ICAM-1), vascular cell adhesion molecule-2 (VCAM-2),
molecules of vascular endothelium and expression of inflam-
matory cascade by CEA molecule favour tumour meta-
stasis.10e12 These molecules also play pivotal role in
pathogenesis of atherosclerosis also. Hence, CEA might be a
common biomarker of atherosclerosis, embolization and
tumourigenesis. Alexiou D et al13 have reported that the
concentrations of cell adhesion molecules (ICAM- 1 and
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Figure 5. Correlation between CEA and CPK-MB in patients with STEMI and
NSTEMI combined together.
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Figure 3. Correlation of serum levels of CEA with CPK-MB in STEMI
patients.
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sclerosis, correlate with CEA in patients with colorectal car-
cinoma. Additionally, CEA may drive plaque evolution to
acute complications like development of ACS. It can formu-
late a hypercoagulable state as well as dysregulations of ma-
trix metalloproteinase as observed in cancer patients.14
Camacho-Leal Pet al reported that it may act as inducer of
CEA related adhesion molecule mediated apoptosis.15 Since
apoptosis is a key event in atherosclerotic plaque unstability
and rupture, the effect of CEA on this pathway could be of
major importance for pathogenesis of ACS.
6. CEA and CPK-MB
Serum levels of CPK-MB are directly related to severity of
ACS, morbidity and mortality16 and we also found signifi-
cantly higher concentration of CPK-MB in patients with
STEMI as compared to NSTEMI/UA patients
(130.95 ± 108.32 IU/dl and 62.19 ± 67.33 IU/dl respectively,
p < 0.001). Mean concentration of CEA in our patients with
ACS (STEMI and NSTEMI/UA groups taken together) was
4.52 ± 2.97 ng/ml indicating highly significant and strong
positive correlation between CEA and CPK-MB concentra-
tions (R ¼ 0.809 and p < 0.001). Moreover, in patients with0
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Figure 4. Correlation of serum levels of CEA with CPK-MB in NSTEMI/UA
patients.STEMI a stronger correlation was found between CEA and
CPK-MB as compared to patients with NSTEMI (R ¼ 0.866
and 0.648 respectively, p < 0.001). A strong correlation was
found when patients with STEMI and NSTEMI together were
analysed (R ¼ 0.781, p < 0.001). However, when patients with
NSTEMI and UA were analysed separately with regard to
correlation between these two markers, a highly significant
and stronger correlation coefficient (R ¼ 0.950 (p < 0.001) in
NSTEMI group was observed but not in UA patients
(R ¼ 0.319 and p ¼ 0.197). The reason for not a statistically
significant correlation between CEA and CPK MB in UA
patients may be because CEA levels may increase significantly
with unstability of a plaque before or even in the absence of
overt myocardial necrosis, while CPK-MB gets raised only
when myocardial necrosis sets in. Unstable angina patients
have no rise of CPK-MB. Yee et al16 evaluated the indepen-
dent prognostic value of CPK-MB in 542 consecutive patients
with ACS. Higher morbidity and mortality was demonstrated
in those with CPK-MB elevation than those without CPK-MB
elevation. It was concluded that serum levels of CPK-MB
significantly identified patients at higher risk of death and
major cardiac events at six months follow-up. Trevelyan J et al
also reported CPK-MB as independent marker of major car-
diovascular deaths at 6 month interval.17 Chia et al reported0
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Figure 6. Correlation of serum levels of CEA with CPK-MB in NSTEMI
patients.
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Figure 7. Correlation of serum levels of CEA with CPK-MB in UA patients.
Table 3
Serum levels of CEA and CPK-MB in patients and their comparison with
qualitative Troponin-T test.
Troponin T þ
(>0.10ng/ml)
(n ¼ 66)
Troponin T -
(<0.10 ng/ml)
(n ¼ 18)
p value
CEA (ng/ml)
Range
4.69 ± 3.26
(0.80e14.90)
3.91 ± 1.40
(1.10e6.80)
<0.001
CPK-MB (IU/dl)
Range
120.13 ± 95.67
(28e486)
10.16 ± 4.03
(4e18)
<0.001
Bold indicate p-value significant at <0.05 and highly significant at <0.001.
16 G.S. Ranga et al. / Journal of Acute Medicine 6 (2016) 11e18significant correlation between CPK-MB and left ventricular
ejection fraction (LEVF)18 which is a powerful prognostic
factor. CPK-MB in patients with acute myocardial infarction
correlates with cardiac magnetic resonance measured infarct
size at 6 months follow up.19
The results of our study also indicate that CPK-MB con-
centration correlates with severity of ACS. We also found that
serum levels of CEA show a strong positive correlation with
CPK-MB levels in patients with myocardial infarction, high-
lighting that CEA also could be a useful prognostic marker
just like CPK-MB. So far no study has been reported corre-
lating CEA with prognostic markers of ACS. So further large
scale trials are warranted in this regard.
A statistically insignificant correlation between CPK-MB
and CEA in patients with UA may be due to significant rise
of CEA but no rise in CPK-MB in UA patients. This further
strengthens the belief that CEA levels may be associated with
disruption/unstablity of atherosclerotic plaque and it can prove
a useful biomarker for diagnosis of ACS including UA even in
the absence of rise of established markers.Figure 8. Correlation of serum levels of CEA with CPK-MB in STEMI plus
NSTEMI patients combined together.7. CEA and Troponin T
The results of our study show that CEA concentration were
significantly higher in ACS patients who were positive for
qualitative Troponin T test (STEMI and NSTEMI patients) as
compared to those who were negative for this test (UA pa-
tients) (4.69 ± 3.26 ng/ml vs 3.91 ± 1.40 ng/ml respectively,
p < 0.001). Further, CEA concentration were significantly
higher in UA patients as compared to stable CAD
(2.04 ± 1.35 ng/dl) and controls (1.91 ± 1.47 ng/ml,
p < 0.001) highlighting that CEA may be a useful biomarker
of ACS even when qualitative tests for Troponins are negative.
One of the drawbacks of Troponins as cardiac biomarkers for
diagnosis of ACS is that their levels get raised only when overt
myocardial necrosis has already taken place. The latest efforts
are directed at discovering a cardiac biomarker whose levels
get raised significantly even before start of actual myocardial
necrosis. A biomarker such as CEA can give physician a
window period to act and prevent myocardial necrosis from
occurring in the first place. This can be helpful in future to
bring down ACS related mortality and morbidity significantly.
It is well known that cardiac pain can present atypically such
as epigastric discomfort, backache, throat pain or even as
toothache, also nonspecific ST segment and T wave changes
can be present in a lot of non cardiac conditions which can be
confused with CAD related changes.20 Early diagnosis of ACS
becomes trickier in the absence of elevation of conventional
biomarkers such as Troponin T and CPK-MB. Ruling out the
possibility of cardiac pain when it presents in atypical manner
with nonspecific ST segment and T wave changes has been
detrimental in certain cases. Early invasive mode of diagnosis
and treatment such as angiography is not afforded by a huge
population belonging to lower economic strata of the society,
especially in resources limited countries. An early blood test
for a biomarker such as CEA can be of immense help in these
situations. Hence, our results showing higher levels of CEA inTable 4
Comparison of CEA levels amongst Troponin T negative ACS (Unstable
angina) patients and controls.
Troponin T -
(<0.10ng/ml)
(n ¼ 18)
Controls
(n ¼ 42)
p value
CEA (ng/ml)
Range
3.91 ± 1.40 (1.10e6.80) 1.91 ± 1.47 (0.20e7.40) <0.001
Bold indicate p-value significant at <0.05 and highly significant at <0.001.
17G.S. Ranga et al. / Journal of Acute Medicine 6 (2016) 11e18Troponin T negative ACS (UA) patients as compared to stable
CAD and controls in this regard are promising.
Previous studies have revealed the positive correlation of
CEA with ACS, if CEA is just correlated with current used
cardiac biomarkers such as cTn, its influence could be limited
because of well-developed cTn assay and specially the rapid
development of efficient point-of-care tests. However, it will
be another story if CEA can predict the coming myocardial
insult as it has been thought to release because of plaque
rupture. It is a little pity that there were only 18 cases of un-
stable angina in this study, though significant difference has
been shown in comparison with stable CAD healthy controlled
group. If more cases of unstable angina are enrolled in future
studies to prove this hypothesis, and a cutoff value can be
obtained to predict the coming event of myocardial necrosis, it
may change our daily practice of acute medicine.
8. Conclusion
CEA is a robust, novel and sensitive biomarker for early
diagnosis of ACS. Its levels correlate with severity of ACS. It
may play a crucial role in diagnosis of ACS in patients who
present with atypical manifestations or when traditional bio-
markers such as CPK-MB and cTn are not raised.
Grant support
No any financial grant taken. Entirely self financed
research.
Financial disclosures
No financial assistance taken from any company, organi-
zation or any government or private enterprise. Entire research
was self financed.
Acknowledgement
We certify that this is our original research work and no
financial grant has been taken from any source. The entire
research is self-financed.Statement of competing interests
There is no competing interest.Abbreviations used in manuscript
CEA Carcinoembryonic antigen
ELISA Enzyme linked immunosorbent assay
STEMI ST segment elevation myocardial infarction
NSTEMI/UA Non ST segment elevation myocardial infarc-
tion/unstable anginaCPK-MB
Creatinine phosphokinase-MB
CAD coronary artery disease
PAPP-A Pregnancy associated plasma protein-A
ICAM-1 Intercellular adhesion molecule-1
VCAM-2
vascular endothelial cells adhesion molecule-2
TMT Treadmill test
ANOVAAnalysis of variance
cTn cardiac TroponinReferences
1. Ruibal Morell A. CEA serum levels in non-neoplastic disease. Int J Biol
Markers. 1992;7(3):160e166.
2. Stevens DP, Mackay IR. Increased carcinoembryonic antigen in heavy
cigarette smokers. Lancet. 1973;2(7840):1238e1239.
3. Witherspoon LR, Shuler SE, Alyea K, et al. Carcinoembryonic antigen:
assay following heat compared with perchloric acid extraction in patients
with colon cancer, non-neoplastic gastrointestinal diseases, or chronic
renal failure. J Nucl Med. 1983;24(10):916e921.
4. Lee JY, Lee HK, Lee DC, Lee JW. Serum carcinoembryonic antigen is
associated with abdominal visceral fat accumulation in female Korean
nonsmokers. PLoS One. 2012;7(8):e43518.
5. Ishizaka N, Ishizaka Y, Toda E, et al. Are serum carcinoembryonic antigen
levels associated with carotid atherosclerosis? Arterioscl Thromb Vasc
Biol. 2008;28:160e165.
6. Vassalle C, Pratali L, Ndreu R, et al. Carcinoembryonic antigen concen-
trations in patients with acute coronary syndrome. Clin Chem Lab Med.
2010;48(9):1339e1343.
7. Thygesen K, Alpert JS, White HD, on behalf of joint ESC/ACCF/AHA/
WHF Task Force for the Redefinition of Myocardial Infarction. Universal
definition ofmyocardial infarction.Circulation. 2007;116(22):2634e2653.
8. Myrtle JF, Shimizu I, Varga M, et al. Creatine Kinase MB isoenzyme
quantitation in serum by simultaneous immunoenzymatic assay. Clin
Chem. 1983;29:1232e1233.
9. Benditt EP, Benditt JM. Evidence for a monoclonal origin of human
atherosclerotic plaque. Proc Natl Acad Sci USA. 1973;70:1753e1756.
10. Aarons CB, Bajenova O, Andrews C, et al. Carcinoembryonic antigen-
stimulated THP-1 macrophages activate endothelial cells and increase
cell-cell adhesion of colorectal cancer cells. Clin Exp Metastasis. 2007;24:
201e209.
11. Minami S, Fruit J, Kanematsu T. Role of carcinoembryonic antigen in the
progression of colon cancer cells that express carbohydrate antigen.
Cancer Res. 2001;61:2732e2735.
12. Gangopadhyay A, Lazure DA, Thomas P. Adhesion of colorectal carci-
noma cells to the endothelium is mediated by cytokines from CEA
stimulated Kupffer cells. Clin Exp Metastasis. 1998;16:703e712.
13. Alexiou D, Karayiannakis AJ, Syrigos KN, et al. Serum levels of E-
selectin, ICAM-1 and VCAM-1 in colorectal cancer patients: correlations
with clinicopathological features, patient survival and tumour surgery. Eur
J Cancer. 2001;37(18):2392e2397.
14. Ishida H, Murata N, Hyashi Y, Tada M, Hashimoto D. Serum levels of
tissue inhibitors of metalloproteinase-1 (TIMI-1) in colorectal cancer
patients. Surg Today. 2003;28:373e378.
15. Camacho-Leal P, Stanners CP. The human carcinoembryonic antigen
(CEA) GPI anchor mediates anoikis inhibition by inactivation of the
intrinsic death path ways. Oncogene. 2008;27:1545e1553.
16. Yee KC, Mukherjee D, Smith DE, et al. Prognostic significance of an
elevated creatine kinase in the absence of an elevated troponin I
during an acute coronary syndrome. Am J Cardiol. 2003;92(12):
1442e1444.
17. Trevelyan J, Needham EWA, Smith SCH, et al. Sources of diagnostic
inaccuracy of conventional versus new diagnostic criteria for myocardial
18 G.S. Ranga et al. / Journal of Acute Medicine 6 (2016) 11e18infarction in an unselected UK population with suspected cardiac chest
pain, and investigation of independent prognostic variables. Heart. 2003;
89(12):1406e1410.
18. Chia S, Senatore F, Raffel C, et al. Utility of cardiac biomarkers in pre-
dicting infarct size, left ventricular function and clinical outcome after
primary percutaneous coronary intervention for ST-segment elevation
myocardial infarction. J Am Coll Cardiol Intv. 2008;1:415e423.19. Rakowaski T, Dziewierz A, Legutko J, et al. Creatine kinase MB assessed
in patients with acute myocardial infarction correlates with cardiac
magnetic resonance infarct size at 6 month followup. Hellenic J Cardiol.
2014;55:4e8.
20. Ryan ET, Pak PH, DeSanctis RW. Myocardial infarction mimicked by
acute cholecystitis. Ann Intern Med. 1992;116(3):218e220.
